Knox Lane has made a strategic investment in Spectrum Science, which ranks No. 4 on O’Dwyer’s roster of healthcare firms with fee income of $48.9M in 2021.
Focused on the pharma, biotech and life science categories, Spectrum has handled clients such as AbbVie, Moderna, Horizon Therapies, Takeda Neuroscience and Regeneron.
Shamik Patel, Knox Lane partner, and Brent Gunderson, principal, said Spectrum delivers game-changing solutions across commercialization, including strategic communications, advertising, clinical trial recruitment, scientific strategy and medical communications.
Jonathan Wilson, Spectrum owner/CEO, said the firm has “built a team, structure and culture that puts people at the center from the clients we serve, to the patients they help, to the colleagues we collaborate with around the world.”
Spectrum has more than 300 staffers in the US and UK.
No comments have been submitted for this story yet.